To characterize the protein expression profiles and identify the molecules associated with tumor angiogenesis, the cellular proteins of human umbilical vein endothelial cells (HUVECs) in response to cancer cell-conditioned medium (CM) prepared from HT1080 human fibrosarcoma cells were analyzed using fluorescence-labeled 2D gel-based proteomics. Most differentially expressed proteins in HT1080-CM-stimulated cells were found to be downregulated (88%) rather than upregulated (12%) based on statistical analysis of protein spot signals. Additionally, we examined the effects of vascular endothelial cell growth factor (VEGF), a proangiogenic factor, on cellular protein expression. In contrast, most differentially expressed proteins were found to be upregulated (59%) rather than downregulated (41%) in VEGF-stimulated HUVECs. Comparative analyses of 29 and 35 protein species identified in CM-stimulated and VEGF-stimulated HUVECs, respectively, revealed the remarkable differences between these two stimulations. Only four proteins were differentially expressed by both treatments: annexin A2, enolase 1, and T-plastin (downregulated by CM but upregulated by VEGF), and RAN (downregulated by both CM and VEGF). These findings provide new information regarding the regulation of protein expression associated with tumor angiogenesis.
Angiogenesis, the development of neovessels from preexisting blood vessels, occurs in various pathologic conditions such as diabetes, rheumatism, and cancer.
1) The processes of tumor angiogenesis is initiated through activation of endothelial cells (ECs) by proangiogenic factors such as vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF). Then, ECs degrade the extracellular matrix (ECM) by secreting matrix metalloproteinases and invade through the ECM. Eventually, ECs proliferate and migrate to construct neovessels.
2) Tumor angiogenesis occurs through complex processes based on the interaction of ECs with surrounding cells such as tumor cells, fibroblasts, stromal cells, and macrophages. Tumor endothelium modulates the expression of various molecules such as VEGF receptor and integrins. 3) VEGF is widely studied for understanding angiogenic mechanisms. 4) VEGF-regulated cellular molecules have been partially characterized by DNA microarray 5) or proteomic analysis using conventional two-dimensional electrophoresis (2-DE). 6) Because cancer cells produce multiple proangiogenic factors and angiogenic inhibitors, 2) cancer cell-conditioned medium (CM) rather than VEGF alone is expected to induce changes in ECs more similar to actual tumor angiogenesis in vitro. However, the cellular proteins associated with CM-induced angiogenesis have not been well characterized.
The proteomic approach is a powerful tool to identify protein molecules useful for biomarkers or therapeutic targets and to better understand protein-protein interactions. 7, 8) Fluorescence-prelabeled two-dimensional difference gel electrophoresis (2D-DIGE) can analyze multiple protein samples in a single gel and it has higher sensitivity, reproducibility, and quantitative accuracy than conventional 2-DE. 9) In this study, we characterized the protein expression profiles and identified the protein molecules of human umbilical vein endothelial cells (HUVECs) in response to stimulation with CM prepared from the human fibrosarcoma cell line HT1080 using 2D-DIGE and matrix-assisted laser desorption/ionization tandem time of flight mass spectrometry (MALDI-TOF/TOF-MS). In addition, we conducted proteomics using VEGF-stimulated HUVECs and analyzed the difference between CM-induced and VEGF-induced changes at the protein molecule level.
MATERIALS AND METHODS
Cell Culture and Preparation of CM HUVECs purchased from Cambrex Corporation were cultured in endothelial cell growth medium (EGM, Cambrex Corporation, Walkersville, MD, U.S.A.). Human fibrosarcoma HT1080 cells were cultured in RPMI 1640 medium supplemented with heat-inactivated 10% fetal bovine serum. To prepare CM, HT1080 cells were cultured to subconfluence, and then the medium was changed to endothelial basal medium (EBM, Cambrex Corporation). After incubation for 24 h, the culture medium was collected, centrifuged at 500ϫg for 10 min, filtrated to remove the cell debris, and used as CM for the following experiments.
Cell Proliferation Assay HUVECs (3ϫ10 4 cells) were seeded and incubated for 24 h. After the medium was changed to EBM (untreated) or HT1080-CM (treated), the cells were further incubated for 48 h. Viable cell density was determined with the crystal violet staining method: The viable cells were stained with 0.1% crystal violet for 15 min. After washing, the dye extracted with 33% acetic acid was measured with absorption at 570 nm.
Tube Formation Assay Growth factor-reduced Matrigel (BD Biosciences, San Diego, CA, U.S.A.) was added to 24-well plates and incubated for 30 min. HUVECs (5ϫ10 4 cells) were seeded in EBM (untreated) or HT1080-CM (treated) on the matrigel-coated plates, and incubated for 18 h. The mi-croscopic images were scanned using Penguin Mate software (Pixera Corporation). The degree of tube formation was quantified by measuring the tube length in six randomly chosen fields using ImageJ software.
Sample Preparation for 2D-DIGE HUVECs were cultured to subconfluence, and then the medium was changed to EBM or HT1080-CM. The cells were further incubated for 24 h. In another experiment, HUVECs were cultured in EBM with or without recombinant human VEGF 165 (20 ng/ml, BD Biosciences) for 48 h. After incubation, the respective cells were harvested and solubilized with lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris-HCl (pH 8.5)) containing complete protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN, U.S.A.). Those cell lysates were centrifuged at 340,000ϫg for 30 min to remove insoluble materials, and the obtained supernatants were dialyzed with a mini dialysis kit (GE Healthcare UK Ltd.) according to manufacturer's recommended protocol. Protein concentration was determined with the Bradford protein assay method (Bio-Rad Laboratories).
2D-DIGE 2D-DIGE was performed following the procedure as described previously. 10) In brief, the extracted proteins were fluorescently labeled with three cyanine dyes, Cy2 (a pooled sample as an internal standard (treated : untreatedϭ 1 : 1)), Cy3 (untreated HUVECs), and Cy5 (CM-or VEGFtreated HUVECs), respectively. The protein samples were incubated for 30 min on ice, and then 10 mM of lysine was added to each sample to quench the reaction. The labeled samples were mixed and used for 2-DE. The first separation was performed with the IPGphor system (GE Healthcare) using IPG strips (pH3-10NL, 24 cm). The IPG strips were rehydrated with CyDye-labeled samples at 20°C for 12 h, and isoelectric focusing (IEF) was performed to a total of 80 kV h with IPGphor at 20°C. The IPG strips were equilibrated for 15 min in equilibration buffer (6 M urea, 30% glycerol, 2% SDS, 50 mM Tris-HCl (pH 8.8) and 10 mg/ml of DTT) and then for 15 min in the same buffer containing 25 mg/ml of iodoacetamide instead of DTT. The equilibrated strips were transferred onto 10% polyacrylamide gel and the gels were electrophoresed.
Image Analysis The 2D-gel images were scanned using a Typhoon 9400 scanner (GE Healthcare) and statistically analyzed with DyCyder software (version 5.0; GE Healthcare). Protein spots that had been abundantly changed above 1.5 or below 0.67 between treated and untreated samples were defined as picking proteins of interest.
8)
Spot Picking and In-Gel Digestion For spot picking, a large amount of protein samples (ca. 500 mg) without fluorescent prelabeling was subjected to 2-DE, and the gel was stained with DeepPurple (GE Healthcare). Protein spots of interest were picked with Ettan Spotpicker (GE Healthcare). The gel pieces picked were destained with 50 mM ammonium bicarbonate/50% acetonitrile (ACN) and dehydrated with ACN. Then, the dried gel pieces were treated with trypsin solution (25 ng/ml) overnight at 37°C. The digested peptides were extracted from the gel pieces with 80% ACN/1% trifuluoroacetic acid (TFA) and concentrated with vacuum centrifugation.
MALDI-TOF/TOF-MS Analysis
The peptide solutions were desalted and concentrated with Zip-Tip C18m (Millipore, Bedford, MA, U.S.A.). Then, the samples were mixed with a-cyano-4-hydroxycinnamic acid and applied onto target plates. MS/MS spectra were obtained using Ultraflex (Bruker Daltonics, Bremen, Germany) in reflector mode and analyzed with flexanalysis software (Bruker Daltonics). Protein identification was carried out with Mascot software against the database of the NCBI.
RESULTS

Proliferation and Tube Formation of HUVECs Stimulated with CM
We first examined the effect of CM on the cellular proliferation and tube formation activities of ECs. The HT1080-CM-treated HUVECs significantly proliferated compared with untreated HUVECs (Fig. 1A) , and accelerated the formation of tube-like structures (Fig. 1B, C) . These results suggest that the molecular changes in HT1080-CMstimulated HUVECs can be expected to reflect the conditions of actual tumor angiogenesis to some extent.
Characterization of Protein Expression Profiles and Identification of Differentially Expressed Proteins in Response to CM Stimulation
We performed proteomic analysis of HT1080-CM-treated HUVECs using 2D-DIGE to characterize the expression profiles and identify protein species associated with CM-induced angiogenesis. The 2D-gel images of the cellular proteins are shown in Fig. 2 .
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Fig. 2. Differentially Expressed Protein Profile in HUVECs Treated with HT1080-CM
Untreated HUVECs (control) and HT1080-CM-treated HUVECs were solubilized, and the extracted proteins were labeled with CyDye (Cy3: control, Cy5: HT1080-CMtreated). Pooled sample (internal standard) was labeled with Cy2. Red spots show the protein species upregulated in expression, and green spots show those downregulated in expression by the treatment with HT1080-CM. Spot numbers correspond to those in Table 1 .
Fig. 5. Differentially Expressed Protein Profile in HUVECs Treated with VEGF
HUVECs stimulated with VEGF (20 ng/ml) were lysed, and the extracted proteins from the cells were labeled with CyDye (Cy3: control, Cy5: VEGF). Pooled sample (internal standard) was labeled with Cy2. Red spots show proteins upregulated in expression, and green spots show those downregulated in expression by treatment with VEGF. Spot numbers correspond to those in Table 2 .
Fig. 3. Mass Spectrometry Analysis of Tryptic Digests of Proteins of Interest
Peptide mass fingerprinting and MS/MS analysis were performed using MALDI-TOF/TOF-MS. Ion peak spectra matched the five peptide sequences of the tryptic digests from spot number 25 in CM-treated HUVECs was detected (A) and MS/MS spectra of the precursor ion at m/zϭ1784.904 were shown (B).
Among 3606 protein spots detected on the 2-D gel, 232 spots were found to be differentially expressed between treated and untreated samples by statistical analysis of protein spot signals using the Decyder program. Surprisingly, most differentially expressed proteins in HT1080-CM-treated ECs were downregulated (204 proteins, 88%) rather than upregulated (28 proteins, 12%) in our proteomics. Among these, 29 protein species were successfully identified by MALDI-TOF/TOF-MS analysis (Table 1, Fig. 3 ), and these could be functionally classified into glycolytic enzymes, protein degradation-related proteins, proteins involved in signal transduction, and others (Table 1) . Two identified proteins, ALDH2 (related to metabolism) and voltage-dependent anion channel 1 (VDAC1), were upregulated by HT1080-CM treatment (Fig. 4) , but all the others were downregulated. The representatives of downregulated proteins and their functional classification were: (1) enolase 1 (ENO1, Fig. 4) , LDHB, GAPDH, PGAM1, and similar to triosephosphate isomerase (glycolytic enzymes); (2) PSMD13, PSMA6, PSMA7, and UCHL1 (protein degradation-related proteins); (3) annexin A2 (ANXA2), RAN (Fig. 4) , and YWHAZ (signal transduction-related proteins); and (4) PRDX6 and 
TXNRD1 (antioxidant enzymes).
Differentially Expressed Proteins in Response to VEGF Stimulation
We additionally analyzed the protein expression changes in HUVECs in response to VEGF stimulation using 2D-DIGE (Fig. 5) . Among 3,924 protein spots detected, 159 proteins were found to be differentially expressed between treated and untreated samples by statistical analysis, and 94 protein spots (59%) were upregulated and 65 (41%) were downregulated. Among these 159 protein spots, 35 species were identified by MALDI-TOF/TOF-MS (Table 2) and these were functionally classified into proteins related to cytoskeletal regulation, protein synthesis, RNA processing, and signal transduction. The differentially expressed proteins and their functional classification represented were: (1) CALD1, GSN, T-plastin (PSL3), and LASP1 (all upregulated, cytoskeleton-regulating proteins); (2) EEF1B2, EEF1D, EEF2, and EEF1A1L14 (all upregulated, protein synthesisrelated proteins); (3) ANXA1, ANXA2 and ANXA5 (all upregulated), and RAN (downregulated) (signal transductionrelated proteins); (4) HNRPC, HNRPA1, RBM8A, and SFRS3 (all downregulated, RNA processing); and (5) SDHA, UQCRC1, COX4NB, and ATP5H (all downregulated, mitochondrial electron transport system). In the identified proteins, some of which are known to be associated with angiogenesis induced by VEGF (HSP90, HSP70, EEF, ENO1, etc.), 6) and others may be novel proteins associated with VEGF-induced angiogenesis (LASP1, RAN, UQCRC1, 
etc.).
Comparison of CM-Induced and VEGF-Induced Angiogenic Response in HUVECs Based on the data as described above, the expression profiles of identified proteins were compared between CM-induced and VEGF-induced response in HUVECs. By statistical analysis of protein spot signals using the Decyder software program, protein expression was predominantly suppressed (88%) rather than induced (12%) by HT1080-CM stimulation, whereas the expression was predominantly induced (59%) rather than suppressed (41%) by VEGF stimulation. As shown in Fig. 6 , the identified protein species in the CM-induced angiogenic response were markedly different from those in the VEGFinduced response. Among the total 60 protein species identified, only four species were either up-or downregulated in both CM and VEGF stimulation (Fig. 6A) . We did not find the proteins upregulated by both CM and VEGF stimulation (Fig. 6B) , but RAN was found to be downregulated by both stimulations (Fig. 6C) . There was no protein upregulated by CM and downregulated by VEGF (Fig. 6D) , while three proteins (ANXA2, ENO1 (Fig. 4) , and PSL3) were found to be downregulated by CM but upregulated by VEGF (Fig. 6E) .
DISCUSSION
Angiogenesis is a critical event for tumor growth and hematogenous metastasis, 1) and VEGF has been well characterized as a regulator of angiogenesis. 4) However, the VEGF stimulation of ECs as an angiogenic model is not thought to reflect the condition of actual tumor angiogenesis. The CM stimulation of ECs is probably a better cellular model for tumor angiogenesis, because cancer cells produce several proangiogenic factors and inhibitors.
2) The CM prepared from HT1080 fibrosarcoma cells enhanced the cell proliferation and tube formation mimicking the tumor angiogenesis processes.
To our knowledge, this proteomic study is the first demonstration that (1) HT1080-CM predominantly induced the downregulation rather than the upregulation of protein expression in HUVECs; (2) the identified proteins of ECs stimulated with CM were considerably different from those stimulated with VEGF; (3) two proteins, ALDH2 and VDAC1, were upregulated by CM in their expression; (4) three proteins, ANXA2, ENO1, and PLS3, were downregulated by CM, but upregulated by VEGF in their expression; and (5) no proteins were found to be upregulated by both CM and VEGF stimulation, but the downregulation of RAN by both was detected.
ALDH2 is a member of the aldehyde dehydrogenase family and is involved in the oxidative pathway of alcohol metabolism. The relationship between alcohol metabolism and cancer progression has previously been well studied, and the acetaldehyde plays a critical role in field cancerization.
11)
Recently, Chen et al. have reported that an inhibitor of aldehyde dehydrogenase, disulfiram (DSF), induced apoptosis in breast cancer cells and suppressed tumor growth. 12) In this study, ALDH2 expression was found to be upregulated by treatment with HT1080-CM but not with VEGF. Inhibition of ALDH2 enzyme activity by certain therapeutic agents may be useful for the suppression of cancer-mediated angiogenesis. VDAC1, an outer membrane protein of mitochondria, is a small and abundant pore-forming protein thought to form the major pathway for the movement of adenine nucleotides through the mitochondrial membrane. This protein is also known as a receptor for plasminogen kringle 5, which induces apoptosis of endothelial cells and regulates angiogenesis.
13) The direct relationship between VDAC1 and angiogenesis, however, is still unclear. Since HT1080-CM-stimulated endothelial cells highly express VDAC1 as well as malignant cells, 14) it might be a candidate as an effective target for cancer therapy.
ANXA2 is a member of the calcium-dependent phospholipid-binding protein family and known to play a role in the regulation of cellular growth and signal transduction. The expression of ANXA2 is known to be upregulated in various types of cancers such as pancreas, breast, and brain 15) and in tumor vasculature, 16) whereas its expression was downregulated in prostate cancer. 17) Since our results showed that ANXA2 expression was downregulated by HT1080-CM but upregulated by VEGF, HT1080-CM treatment may cause a response similar to prostate cancer. ANXA2 is also a cell surface receptor for angiostatin, which is a potent endoge- 19, 20) It is possible that the downregulation of ANXA2 expression by HT1080-CM promotes CM-induced angiogenesis through the suppression of the effect of angiostatin.
ENO1 is a glycolytic enzyme and has been found to bind to an element in the c-myc promoter. Recently, it has been reported that ENO1 suppresses prostate cancer cell growth and induces neuroblastoma cell death. 21, 22) Hence the downregulation of ENO1 induced by HT1080-CM might promote endothelial cell growth.
PLS3 is a member of an important actin-filament crosslinking protein family and controls cell motility by the maintenance of the actin cytoskeleton. This protein enhances actin base cell movement mediated by the Wiskott/Aldrich-symdrom protein (WASP). 23) Since WASP plays an important role in endothelial cell movement, 24) PLS3 might be associated with cellular motility during the HT1080-CM-regulated angiogenic response.
RAN is a small GTP-binding and Ras-related nuclear protein with an important role in the transport of RNA and proteins through the nuclear pore complex. This protein positively regulates the nuclear localization of PTEN, one of the important tumor-suppressor gene products, and nuclear PTEN is known to enhance apoptosis. 25) PTEN negatively controls the Akt signal-transduction pathway and is also closely associated with angiogenesis. 26) Downregulation of RAN by CM and VEGF might suppress the nuclear translocation of PTEN and promote angiogenesis.
In addition to these proteins, we identified some functional protein molecules that may be involved in CM-induced angiogenic response, such as glycolytic enzymes, protein degradation-related proteins, and antioxidant enzymes. Among them, UCHL1, which plays a role in proteasomal protein degradation, was reported to be reduced in metastatic melanoma and showed inhibitory effects on the metastasis of melanoma. 27) As mentioned above, the differential expression of ALDH2, VDAC1, ANXA2, ENO1, PLS3, RAN, etc. in HT1080-CM-induced angiogenesis seems to be associated with cancer cell-mediated angiogenesis. Thus our data provide new information regarding the regulation of protein expression associated with tumor-induced angiogenesis and will be helpful in understanding the molecular mechanisms of tumor angiogenesis. Vol. 30, No. 12 
